Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 3/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26633347 | 0.85 | GSK3B (0.42) | GSK3BDYRK1ASYKAAK1GCK | |
| SCHEMBL25347433 | 0.83 | GSK3B (0.44) | GSK3BDYRK1AALDH1A1GAAAAK1 | |
| SCHEMBL15354547 | 0.83 | GSK3B (0.44) | GSK3BDYRK1AALDH1A1GAAAAK1 | |
| SCHEMBL5908666 | 0.83 | GSK3B (0.46) | GSK3BDYRK1ASYKHCRTR1HCRTR2 | |
| SCHEMBL9109967 | 0.82 | ATR (0.48) | GSK3BDYRK1ASYKAAK1ATR | |
| SCHEMBL22448769 | 0.82 | GSK3B (0.43) | GSK3BDYRK1AALDH1A1GAAAAK1 | |
| SCHEMBL20049586 | 0.82 | GSK3B (0.45) | GSK3BDYRK1ASYKAAK1ATR | |
| SCHEMBL28641960 | 0.82 | GSK3B (0.45) | GSK3BDYRK1ASYKAAK1ATR | |
| SCHEMBL26757694 | 0.82 | GSK3B (0.41) | GSK3BDYRK1ASYKALDH1A1GAA | |
| SCHEMBL31399688 | 0.82 | GSK3B (0.41) | GSK3BDYRK1ASYKALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021108404-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | GSK3B 2369/4885DYRK1A 788/4885SYK 1239/4885 |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | GSK3B 1029/4885DYRK1A 3907/4885SYK 4604/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | GSK3B 1029/4885DYRK1A 3907/4885SYK 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.